Featured Press Releases

Evogene and Verb Biotics Enter Collaboration Agreement to Advance Probiotic Innovation

Evogene and Verb Biotics Enter Collaboration Agreement to Advance Probiotic Innovation

OncoIncytes Launched by 1Cell.Ai (Previously OneCell Diagnostics) to Integrate Multi-Modal Data for Precision Oncology

OncoIncytes Launched by 1Cell.Ai (Previously OneCell Diagnostics) to Integrate Multi-Modal Data for Precision Oncology

  • 22 Apr 2025

OneCell Diagnostics announced its launch of OncoIncytes, a comprehensive multi-modal cancer...

Apotex Corp. Introduces Generic Fertility Treatment Injectable Cetrorelix® in the United States

Apotex Corp. Introduces Generic Fertility Treatment Injectable Cetrorelix® in the United States

Beckman Coulter

Beckman Coulter's DxI 9000 Immunoassay Analyzer

Seraphina Therapeutics Announces C15:0 Reverses Key Aspects of Cellular Fragility Syndrome in a Second Model

Seraphina Therapeutics Announces C15:0 Reverses Key Aspects of Cellular Fragility Syndrome in a Second Model

Unique Mouse Model Enables genOway to Transform Prediction of Antibody Therapies in Humans

Unique Mouse Model Enables genOway to Transform Prediction of Antibody Therapies in Humans

Apertura Gene Therapy and Broad Institute scientists share data on TfR1 CapX™, a novel CNS-targeting capsid

Apertura Gene Therapy and Broad Institute scientists share data on TfR1 CapX™, a novel CNS-targeting capsid

  • Apertura Gene Therapy
  • 28 Apr 2026
AbbVie submits FDA application for SKYRIZI® (risankizumab-rzaa) subcutaneous induction in adults with moderate to severe Crohn’s disease

AbbVie submits FDA application for SKYRIZI® (risankizumab-rzaa) subcutaneous induction in adults with moderate to severe Crohn’s disease

  • AbbVie
  • 28 Apr 2026
Mundipharma reports positive Phase III ReSPECT results for REZZAYO® (rezafungin) in preventing invasive fungal diseases in stem cell transplant patients

Mundipharma reports positive Phase III ReSPECT results for REZZAYO® (rezafungin) in preventing invasive fungal diseases in stem cell transplant patients

  • Mundipharma
  • 28 Apr 2026
Cellenkos, Inc. receives FDA clearance to begin Phase 2 trial of CK0801 (allogeneic cord blood-derived Tregs) for aplastic anemia

Cellenkos, Inc. receives FDA clearance to begin Phase 2 trial of CK0801 (allogeneic cord blood-derived Tregs) for aplastic anemia

  • Cellenkos, Inc.
  • 27 Apr 2026
Ascletis announces completion of enrollment in its U.S. Phase II study evaluating ASC30, an oral small-molecule GLP-1R agonist, for diabetes treatment

Ascletis announces completion of enrollment in its U.S. Phase II study evaluating ASC30, an oral small-molecule GLP-1R agonist, for diabetes treatment

  • Ascletis Pharma Inc.
  • 27 Apr 2026
OrthoTrophix reports new findings on TPX-100, revealing a structural relationship between femoral bone shape and meniscal pathology in knee osteoarthritis

OrthoTrophix reports new findings on TPX-100, revealing a structural relationship between femoral bone shape and meniscal pathology in knee osteoarthritis

  • OrthoTrophix, Inc.
  • 26 Apr 2026
The Digital Pharma Advances Conference 2026

Most Popular
April   2026
M T W T F S S
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30      

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.